Logo

• Finished gynecological cancer (KGOG1002)

  A prospective, multi-center, open-label, randomized, controlled study to evaluate the use of IV Iron Sucrose (Venoferrum®) in the prevention of anemia in patients with cervical cancer receiving concurrent chemoradiotherapy

  • PI / PI기관 Young Tae Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-29
  • Current Enrollment / Estimated Enrollment 26 person / 80 person (32.5%)

• Finished gynecological cancer (KGOG1001)

  A Phase II Trial of Radiation Therapy with Concurrent Palitaxel/Carboplatin Chemotherapy in High-risk Cervical Cancer Patients after Radical Hysterectomy

  • PI / PI기관 Soon-Beom Kang /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-29
  • Current Enrollment / Estimated Enrollment 71 person / 71 person (100.0%)

• Finished gynecological cancer (KGOG3018)

  GCIG/AGO-OVAR16: A phase III study to evaluate the efficacy and safety of pazopanib monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer

  • PI / PI기관 Jae-Weon Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-29
  • Current Enrollment / Estimated Enrollment 56 person / 900 person (6.2%)

• Finished gynecological cancer (KGOG3041)

  Retrospective-REBECA: Real-world effectiveness of bevacizumab based on aurelia in platinum-resistant recurrent ovarian cancer

  • PI / PI기관 Jung-Yun Lee /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-29
  • Current Enrollment / Estimated Enrollment 391 person / 300 person (130.29999999999998%)

• Finished gynecological cancer (KGOG3040)

  Validation of the Functional assessment of cancer therapy - NCCN Fact Ovarian Symptom Index (NFOSI-18) & Neurotoxicity (NTX-4) for patients with ovarian cancer

  • PI / PI기관 Kidong Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-29
  • Current Enrollment / Estimated Enrollment 250 person / 200 person (125.0%)

• Finished gynecological cancer (KGOG3021)

  • PI / PI기관 김용만 /
  • Registration Date / Last Update Posted 2022-04-22 / 2022-04-22
  • Current Enrollment / Estimated Enrollment 102 person / 100 person (102.0%)

• gynecological cancer (KGOG3054R)

  Retrospective-Characterization of ovarian cancer patients with somatic BRCA wild and germline BRCA mutation (SORA)

  • PI / PI기관 Kidong Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2022-05-10
  • Current Enrollment / Estimated Enrollment 0 person / 300 person (0.0%)

• gynecological cancer (KGOG3036)

  NRG-GY004: Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

  • PI / PI기관 Jae-Weon Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2022-05-10
  • Current Enrollment / Estimated Enrollment 579 person / 561 person (103.2%)

* (사)대한부인종양연구회는 게시된 세부 임상연구 정보에 대해 법적 책임이 없습니다.